To access this element change to forms mode OFF
Grant Award View - GA271299
Using advanced structural biology to exploit BCL2 effector proteins for...
GA ID:
GA271299
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
1-Sep-2022
Publish Date:
31-Oct-2022
Category:
Medical Research
Grant Term:
1-Jan-2023 to 31-Dec-2027
Value (AUD):
$1,624,029.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 21/22 1.1 Health and Medical Research
Grant Program:
Investigator Grants
Grant Activity:
Using advanced structural biology to exploit BCL2 effector proteins for new tailored therapies.
Purpose:
This research aims to identify new cancer drugs like venetoclax, which has revolutionised leukemia therapy by targeting one of eight BCL2 family proteins involved in cell death. Using Australia’s leading facilities, eg. the National Drug Discovery Center and Australian Synchrotron, this research will investigate the structure and function of three additional BCL2 proteins. This is expected to lead to new classes of drugs that can treat diseases where current therapies fail.
GO ID:
GO Title:
Investigator Grants 2022
Internal Reference ID:
2022/GNT2016894
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
The Walter and Eliza Hall Institute of Medical Research
Recipient ABN:
12 004 251 423
Grant Recipient Location
Suburb:
Parkville
Town/City:
Parkville
Postcode:
3052
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
Country:
AUSTRALIA